Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 5/20 | 0.76 |
| ▸ | CCND1 | P24385 | 5/20 | 0.76 |
| ▸ | HTR2A | P28223 | 1/20 | 0.59 |
| ▸ | HTR2C | P28335 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HTR6 | P50406 | 1/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.48 |
| ▸ | DAO | P14920 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29379363 | 1.00 | CDK4 (0.76) | CDK4CCND1HTR2AHTR2CLMNA | |
| SCHEMBL11366447 | 0.87 | CDK4 (1.00) | CDK4CCND1HTR2AHTR2CLMNA | |
| SCHEMBL28616424 | 0.85 | CDK4 (0.82) | CDK4CCND1HTR2AHTR2CLMNA | |
| SCHEMBL1120445 | 0.83 | CDK4 (0.76) | CDK4CCND1HTR2AHTR2CLMNA | |
| SCHEMBL6125407 | 0.83 | CDK4 (0.68) | CDK4CCND1HTR2AHTR2CLMNA | |
| Hydrochloric Acid SCHEMBL6258190 | 0.82 | CDK4 (0.73) | CDK4CCND1HTR2AHTR2CLMNA | |
| SCHEMBL135070 | 0.80 | CDK4 (0.78) | CDK4CCND1HTR2AHTR2CLMNA | |
| SCHEMBL3347874 | 0.79 | CDK4 (0.76) | CDK4CCND1HTR2AHTR2CLMNA | |
| SCHEMBL3134501 | 0.79 | CDK4 (0.76) | CDK4CCND1HTR2AHTR2CLMNA | |
| SCHEMBL3330892 | 0.79 | CDK4 (0.76) | CDK4CCND1HTR2AHTR2CLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112457298-B | Substituted 2-anilinopyrimidine derivatives and their use as epidermal growth factor receptor modulators | 贝达医药公司 | 2024-05-07 | — | — | CN | disclosed |
| CN-112375067-B | Substituted 2-anilinopyrimidine derivatives and their use as epidermal growth factor receptor modulators | 贝达医药公司 | 2024-03-15 | — | — | CN | disclosed |
| US-11414401-B2 | Substituted 2-anilinopyrimidine derivatives as EGFR modulators | BETA PHARMA INC. (US) | 2022-08-16 | — | — | US | disclosed |
| CN-112457298-A | Substituted 2-anilinopyrimidine derivatives and their use as epidermal growth factor receptor modulators | 贝达医药公司 | 2021-03-09 | — | — | CN | disclosed |
| CN-112375067-A | Substituted 2-anilinopyrimidine derivatives and their use as epidermal growth factor receptor modulators | 贝达医药公司 | 2021-02-19 | — | — | CN | disclosed |
| CN-108024993-B | Substituted 2-anilinopyrimidine derivatives and their use as epidermal growth factor receptor modulators | 贝达医药公司 | 2020-11-06 | — | — | CN | disclosed |
| US-20200216421-A1 | SUBSTITUTED 2-ANILINOPYRIMIDINE DERIVATIVES AS EGFR MODULATORS | BETA PHARMA, INC. (US) | 2020-07-09 | — | — | US | disclosed |
| US-10590111-B2 | Substituted 2-anilinopyrimidine derivatives as EGFR modulators | BETA PHARMA, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| WO-2018132636-A1 | [18F]MALEIMIDE-BASED GLYCOGEN SYNTHASE KINASE-3BETA LIGANDS FOR POSITRON EMISSION TOMOGRAPHY IMAGING AND RADIOSYNTHESIS METHOD | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2018-07-19 | — | — | WO | disclosed |
| CN-108024993-A | Substituted 2-anilinopyrimidine derivatives and their use as epidermal growth factor receptor modulators | 贝达医药公司 | 2018-05-11 | — | — | CN | disclosed |
| US-20170362203-A1 | SUBSTITUTED 2-ANILINOPYRIMIDINE DERIVATIVES AS EGFR MODULATORS | BETA PHARMA, INC. (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170362203-A1 | SUBSTITUTED 2-ANILINOPYRIMIDINE DERIVATIVES AS EGFR MODULATORS | BETA PHARMA, INC. (US) | 2017-12-21 | — | — | US | disclosed |
| EP-3229798-A2 | SUBSTITUTED 2-ANILINOPYRIMIDINE DERIVATIVES AS EGFR MODULATORS | Beta Pharma, Inc. (US) | 2017-10-18 | — | — | EP | disclosed |
| WO-2016094821-A2 | SUBSTITUTED 2-ANILINOPYRIMIDINE DERIVATIVES AS EGFR MODULATORS | BETA PHARMA, INC. (US) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10590111-B2 | Substituted 2-anilinopyrimidine derivatives as EGFR modulators | EGFR, ERBB2, ERBB4 | CDK4 143/4885CCND1 962/4885HTR2A 1979/4885 |
| US-20200216421-A1 | SUBSTITUTED 2-ANILINOPYRIMIDINE DERIVATIVES AS EGFR MODULATORS | EGFR, ERBB2, ERBB4 | CDK4 143/4885CCND1 962/4885HTR2A 1979/4885 |
| US-11414401-B2 | Substituted 2-anilinopyrimidine derivatives as EGFR modulators | EGFR, ERBB2, ERBB4 | CDK4 143/4885CCND1 962/4885HTR2A 1979/4885 |
| US-20170362203-A1 | SUBSTITUTED 2-ANILINOPYRIMIDINE DERIVATIVES AS EGFR MODULATORS | EGFR, ERBB2, ERBB4 | CDK4 143/4885CCND1 962/4885HTR2A 1979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.